Figure 17

YD0171 induces HCT116 tumor regression in nude mice. Mice were subjected to implantation of HCT116 tumors. When a small palpable tumor was evident at 7 d, the mice were randomized into a vehicle-treated group and a group treated with YD0171 (3 mg/kg/d). In the YD0171-treated animals, treatment discontinued on d 42. In vehicle-treated animals, on d 50, treatment with YD0171 commenced. Pretreatment with YD0171 at the onset of the study prevented the growth of the tumors; discontinuation of the YD0171 treatment allowed tumor growth to commence. Data are shown as mean ± SEM of n = 8 animals per group; *p < 0.05 and **p < 0.01 indicate a significant inhibitory effect of YD0171 compared with the corresponding vehicle control at the same time point.